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ABSTRACT 
A neuroprotective role for epigenetic regulator Tip60 in multiple neurological 
disorders 
Renee Elisha Snook 
 
 
 
 
The advancing field of epigenetics focuses on the changes in phenotypes 
based on alterations in the chromatin structure rather than DNA mutations.  
Neurodegenerative diseases are of particular interest due to the devastating 
effects on the mind and body of those afflicted.  Histone modifications through 
histone acetyltransferases (HATs) and histone deacetylases (HDACs) are 
common epigenetic alterations that occur in an array of neurological disorders.  
Our laboratory previously demonstrated that the HAT Tip60 plays a 
neuroprotective role in multiple cognitive processes impaired in Alzheimer’s 
disease.   Intriguingly, studies in animal models and post mortem brain tissues 
show that Huntington’s disease, Parkinson’s disease, and amyotrophic lateral 
sclerosis (ALS) all have one thing in common and that is a reduction of histone 
acetylation levels in the brain.  Based on these observations, the hypothesis tested 
is that increasing Tip60 levels will induce neuroprotection by restoring 
HAT/HDAC balance and neural gene expression profiles disrupted in each of 
these diseases.   To test my hypothesis, I induced increased levels of Tip60 
specifically in the learning and memory center of the fly brain (termed the 
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mushroom body) in Drosophila that model Huntington’s disease, Parkinson’s 
disease or ALS. An array of behavioral assays such as larvae crawling and 
longevity assays were used to determine whether increased Tip60 restores neural 
circuitry and function. These results may lay the groundwork for broad 
understanding of a potential neuroprotective role for Tip60 HAT action in 
multiple neurological disorders.  
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CHAPTER I: BACKGROUND AND SIGNIFICANCE 
Epigenetics 
Epigenetics is an advancing field that focuses on the changes of 
phenotypes based on variations and modifications to the chromatin structure, 
rather than DNA mutations. The epigenome is deemed such because “epi” is 
derived from the Greek words meaning “over” or “above”; thus translating to 
what is above the genome (Pirooznia and Elefant 2013). Scientists are looking to 
epigenetics to better understand the mechanisms behind various diseases 
(Weinhold 2006).   
Chromatin Packaging and Post-Translational Modifications 
Chromatin packaging plays a large role in epigenetics.  Chromatin is the 
three dimensional structure comprised of the DNA double helix that is wrapped 
around histone octomers. These octomer globular proteins consist of duplicates 
of H2A, H2B, H3, and H4 and are positively charged. Negatively charged DNA 
is able to bind tightly with histones- creating the nucleosome (Annunziato 2008; 
Berger 2007). Extending out from the histone core are the N- and C- terminal 
ends of histone proteins, which are referred to as histone tails. These histone tails 
control the packaging of chromatin based on the chemical groups bound to it 
(Arya and Schlick 2006). These post-translational modifications (PTM) can be 
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categorized into three types: readers, writers, and erasers (Bannister and 
Kouzarides 2011). Writers add chemical groups, or epigenetic marks, to amino 
acid residues on the histone tails to initiate gene expression or silencing.  These 
include histone acetyltransferases (HATs), histone methyltransferases (HMTs), 
protein arginine methyltransferases (PRMTs) and kinases. Histone deacetylases 
(HDACs), lysine demethylases (KDMs) and phosphatases removes the epigenetic 
marks that writers add- termed erasers (Falkenberg and Johnstone 2015). 
Readers, such as proteins containing bromodomains, chromodomains and Tudor 
domains, bind to the epigenetic marks laid down by writers. These do not alter 
the chromatin packaging in anyway, but do affect the functional outcome of 
these post-translational modifications. Writers, erasers, and readers must have a 
balance so gene expression is regulated properly (Yun et al.2011; Falkenberg and 
Johnstone 2015).  
Histone Modifications  
Histone modifications are specific PTM that affects the binding affinity of 
DNA to histones, which regulates gene expression, chromatin structure, and 
nuclear processes. These modifications are also the only kind that can be passed 
down to daughter cells- shown as epigenetic marks (Yun et al.2011). However, 
these marks have been found to become erased after several generations. 
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Previous studies have also shown that these changes can occur not only during 
development, but throughout a person’s lifetime. Scientists have studied 
multiple identical twins and evaluated their DNA to determine how similar it 
was to their twin. They found that younger twins, and those who have lived 
similar lifestyles, had very similar DNA modifications; whereas older twins, and 
those who have not spent a lot of time together, had different modification 
patterns, and in different tissues (Weinhold 2006). Another study that 
demonstrated the effects of epigenetics in subsequent generations is that of 
Waterland and Jirtle in 2003. They found that the fur color of a mouse’s offspring 
was directly correlated to the mother’s nutrition during pregnancy: specifically 
the content of vitamin B12, folic acid, choline, and betaine. The color change was 
due to variations in the DNA methylation caused by the nutrient levels. They 
later found that the DNA methylation also protected the offspring from obesity 
once they reached adulthood (Waterland and Jirtle 2003). 
Histone acetyltransferases (HAT’s) are writers that use acetyl CoA as 
cofactor and transfer an acetyl group to the ε-amino group of a lysine side chain 
on histone tails. When this binding occurs, it neutralizes the positively charged 
lysine and reduces the interaction between the histones and DNA. This 
essentially opens the chromatin structure and allows genes to be transcribed, and 
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therefore expressed (Bannister and Kouzarides 2011; Lee and Workman 2007). 
HAT’s can be categorized into two classes: Type-A and Type-B.  Type-A HAT’s 
are nuclear enzymes that affect the chromatin and transcriptional activity (Kelly 
et al.2000). GNAT, MYST and CBP/p300 are some of the families within this type 
(Bannister and Kouzarides 2011).  Type-B HATs are primarily cytoplasmic and 
acetylate free histones, but not those already used in the chromatin. Acetylation 
of certain newly synthesized histones provides an important role in placing 
histones that had their marks already removed (Bannister and Kouzarides 2011).  
Histone deacetyltransferases (HDAC’s) are erasers that reverse the effects 
of HAT’s, in that they remove the acetyl groups placed on the histone tails. This 
causes the chromatin structure to become more condensed and inhibit 
transcription from occurring, repressing gene expression (Legube and Trouche 
2003). HDAC’s are categorized into four classes (I, II, III, IV) based on their 
similarity to yeast counterparts- which were first identified in Saccharomyces 
cerevisiae. HDAC’s that are dependent on Zn2+ for their deacetylase activity form 
Classes I, II and IV. Class I HDACs are closely related to yeast RPD3 and are 
comprised of HDAC1, HDAC2, HDAC3 and HDAC8. Class II HDAC’s are 
related to yeast HDA1 and are divided into subclass IIa (HDAC4, HDAC5, 
HDAC7 and HDAC9) and subclass IIb (HDAC6 and HDAC10). Seven sirtuins 
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make up Class III HDAC’s. These proteins require the NAD+ cofactor for activity. 
And finally; Class IV HDAC’s contain only HDAC11. (Delcuve et al.2013).  
 
Tip60 (Tat interactive protein, 60 kDa)  
Tip60 (KAT5 in humans) was first identified as a cofactor for the HIV Tat 
protein. It later was found to be a cofactor of several transcription factors, 
including human immunodeficiency virus, type 1 Tat, amyloid precursor 
protein, STAT3, and CCAAT/enhancer-binding protein (Yi et al.2014). It has been 
found that Tip60 contains an evolutionarily conserved region which includes the 
HAT domain and is shared among many Tip60 homologue proteins (Hlubek et 
al.2001). Tip60 belongs to a subgroup of nuclear HAT proteins that are associated 
with transcriptional activity in the MYST family and has also shown to have an 
important role in double strand DNA break repair (Hlubek et al.2001; Voss and 
Thomas 2009). MYST (Moz, Ybf2, Sas3, Sas2, Tip60) proteins are the largest 
family of HAT’s and they are present in all eukaryotic organisms. Some studies 
have suggested that translocations in MYST proteins can cause various diseases 
to develop (Voss and Thomas 2009).   
 Regulation of histone acetylation is important to maintaining a healthy 
balance. In a 2014 study by Yi et. al, the researchers wanted to determine which 
HDAC(s) would deacetylate Tip60. Through successive deacetylation assays, 
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they found that HDAC3 dose-dependently reduced Tip60 acetylation levels. 
When they down regulated HDAC3 in in cells, acetylation levels of Tip60 
increased. These results provided evidence for the importance of HAT/HDAC 
balance, and in this case, Tip60/HDAC3 balances (Yi et al.2014). 
Tip60 has been found to acetylate non-histone proteins as well. Lysine K120 
on p53 at a DNA binding domain is acetylated by Tip60- p53 is a protein that has 
sequence-specific DNA-binding transcription factor (Zhao et al 2006). This, along 
with fellow MYST family member MOF, is able to mediate the expression of 
genes involved in DNA damage, which can induce apoptosis (Spange et al 2009). 
Another study revealed that Tip60 acetylates ATM (ataxia telangiectasia mutant) 
protein kinase. This protein regulates the cell's response to DNA damage 
through the phosphorylation of proteins involved in cell-cycle checkpoints as 
well as DNA repair. They found that ATM can only be activated when a 
functional Tip60 protein is present- highlighting the importance of Tip60 in DNA 
repair and cell homeostasis (Sun et al 2005).  
There are 18 HATs found in the mammalian adult brain, and Tip60 (Kat5) 
has been found to be a close second in abundance. This abundance in the brain 
suggests an important role in neuronal function thus making it a viable 
candidate for neuronal disease study (Stilling et al 2014). 
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Epigenetics in Disease 
Diseases that have been studied in the past, and were found to involve 
epigenetic changes, are various cancers, immune system defects (including 
lupus) and neurodegenerative disorders. Neurodegenerative disorders are of 
particular interest due to the devastating effects on the mind and body of those 
afflicted (Montie and Durcan 2013).  This refers to any disease that causes 
progressive loss of structure or function of neurons, including death of neurons, 
which leads to various debilitating symptoms. These diseases include, but are 
not limited to, Alzheimer’s disease, Huntington’s disease, Fragile X Syndrome, 
Autism, Parkinson’s disease, epilepsy, and amyotrophic lateral sclerosis (ALS). 
Currently, there are no cures for these diseases so it is critical for research on this 
topic to be a priority (Montie and Durcan 2013). Predominantly, DNA 
methylation, protein phosphorylation, and histone modifications are the 
epigenetic changes that occur in these, as well as many other, diseases (Weinhold 
2006).  There are several eukaryotic model organisms that have been utilized to 
study the epigenetics of diseases: Saccharomyces cerevisiae (yeast), Mus musculus 
(mice), Caenorhabditis elegans (nematode), Drosophila melanogaster (fruit fly).  
Drosophila models are fairly simple and convenient creatures for 
experimentation and are often chosen for these reasons (Hunter 2008).  
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Model Organism- Drosophila 
Life Cycle 
 Drosophila is a holometabolous insect, which means it is an insect that has 
a larval and a pupal stage prior to entering the adult stage. This is in contrast to 
insects that have a nymph stage before becoming adults: hemimetabolous. After 
mating, 0.5mm long eggs are immediately laid within rotting fruit, or lab media. 
After about 22-24 hours, larvae will hatch into the medium (Ashburner et al 
2005). There are three stages of larvae, each with undergo molting between 
stages and will become larger in each stage. L1 and L2 instar larvae last 24 hours 
each while third instar (L3) lasts 48 hours. L1 larvae can be seen feeding on the 
surface of the medium and L2 larvae are partially buried in the medium. Once 
larvae enter the L3 stage, they begin to fully burrow into the food and will 
continue to feed. Feeding lasts around 110 hours after the eggs have been laid 
and ceases towards the end of the L3 stage (Ashburner et al 2005). It is at this 
point that the larvae begin to venture out of the food in search of a place to 
pupate; pupation occurs roughly 120 hours after eggs have been laid. Drosophila 
is in pupation for about 4-4.5 days, after which adults emerge. These adults have 
very little pigmentation, and are relatively long and thin. Wings will fully 
expand after an hour and full pigmentation develops aver 2-3 hours. Since 
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females are not receptive to mating directly after hatching, virgin females in a 
laboratory setting could be collected for use in genetic crosses. After 12-14 hours, 
females can be mated and the cycle may continue (Ashburner et al 2005).  
Model Organism 
Drosophila as a model organism for disease has been used since the early 
1900’s. This model has led scientists to the discovery of several important genetic 
milestones; such as, heredity by chromosomes (Morgan 1910), x-ray induced 
mutations (Muller and Altenburg 1930), and early embryonic development 
(Nüsslein-Volhard 1977). All of these accomplishments have led to the complete 
sequencing of the Drosophila genome to create “Flybase”: an online database of 
fruit fly genes in comparison to the human genome. This comparison is crucial to 
the study of human diseases since 75% of known human disease genes have fruit 
fly orthologues (Jennings 2011).  Nearly 13,600 protein-coding genes are situated 
in only four chromosomes and its complex brain, behavior, and anatomy is 
widely studied and understood. Drosophila is an inexpensive model and has a 
relatively short lifespan, surviving up to 120 days, as well as a short generation 
time, around 10 days. This allows genetic crosses and subsequent generations to 
be quickly and easily observed. Drosophila is an ideal model organism for 
neurodegenerative disorders because of the aforementioned biological aspects as 
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well as the behavioral assays that can be performed; including but not limited to, 
larvae and adult crawling, flight ability, and memory and learning ability 
(Prüßing et al.2013). Studying the epigenetics of neurodegenerative disorders in 
Drosophila would be inexpensive and intriguing as well as deeply insightful as to 
what could possibly be viable treatments in humans in the future.   
Mushroom Body 
A particularly interesting part of Drosophila anatomy is the mushroom 
body (MB). This structure is found in the Drosophila brain, as well as in 
honeybees, ants, crickets and other insects (Heisenberg 1998). The mushroom 
body is the learning and memory center of the brain as well as analogous to the 
hippocampus in the human brain (Heisenberg et al.1985; Davis 1993). In flies, the 
MB is comprised of 2500 densely packed parallel neurons- Kenyon cells 
(Schürmann 1987; Kenyon 1896).  The MB consists of 3 parts: 2 lobes and a stalk.  
The stalk, also known as calyx or peduncle, is a cup shaped protrusion 
connecting the lobes. The α-lobes in the MB branch in a vertical direction while 
the β-lobes run in a medial direction (Schürmann 1987). This structure, while 
important, was previously thought to only effect behavior and not its ability to 
fly, walk, eat or reproduce (Wolf et al.1998). Locomotive function was later found 
to be a feature with MB morphology. Various degrees for walking activity have 
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been measured in flies lacking mushroom bodies, due to mutation. These flies 
displayed increased walking activity when compared to wild-type flies. These 
results alluded to the importance of MB morphology and locomotive behaviors 
(Martin et al.1998; Zars 2000).  
Gal4-UAS System 
The Gal4-UAS system is widely used in Drosophila studies to specifically 
target expression of a transgene. Gal4 was first identified as a regulator of genes 
in the yeast Saccharomyces cerevisiae (Oshima 1982).   Gal4 directly binds to four 
related 17 base pair sites between the divergently transcribed GAL10 and GAL1 
genes. An Upstream Activating Sequence (UAS) element is defined by these sites 
and is analogous to the one found in multicellular eukaryotes-like Drosophila (Ma 
and Ptashne 1987). A study by Brand and Perrimon in 1993 focused on using 
Gal4 to control the expression of a particular gene of interest based on the 
presence or absence of an UAS element. The Gal4 driver chosen is tissue/cell 
specific so that the gene controlled by UAS is only expressed in the targeted cell 
type determined by Gal4 (Brand and Perrimon 1993).  
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Neurodegenerative Diseases 
 Neurodegenerative disease is an umbrella term that refers to any disease 
that affects neuronal cells and causes cell death by triggering apoptotic 
pathways. Diseases such as Alzheimer’s, Huntington’s, Parkinson’s, and ALS are 
common neurodegenerative diseases. Each of these has specific genetic 
components that contribute to the disease pathogenesis (Bredesen et al.2006).  
Alzheimer’s Disease 
Alzheimer’s disease is the most common form of dementia; which refers 
to the loss of cognitive function due to the death or abnormal function of 
neurons. The main causes of this loss of function are neurofibrillary tangles and 
amyloid beta (aβ) plaques. Tangles are formed by insoluble and highly stable 
polymers of the microtubule-associated proteins called tau. This protein can 
become twisted inside the neuron and cause death. Aβ plaques occur outside the 
cells and form when the amyloid protein is cleaved incorrectly, which surrounds 
the dendrites and axons (Selkoe 2004; Gaugler et al.2016).  The changes in brain 
function that occurs lead to memory and behavior abilities that ultimately result 
in loss of control over basic bodily functions, such as walking and swallowing 
(Gaugler et al.2013).  
13 
 
 
 
In 2016, it was estimated that 5.2 million Americans over the age of 65 
were afflicted with AD with over two-thirds being women; however, AD is 
commonly underdiagnosed and underreported. It is also projected that the 
number of people who develop Alzheimer’s disease will double by 2050. Due to 
the complications that arise, patients survive 4-8 years on average before 
succumbing to AD (Gaugler et al.2016). The staggering number of afflicted 
individuals indicates the importance of research for treatments and possible 
cures.  
Huntington’s Disease 
Huntington’s disease is an autosomal dominant disorder caused by an 
abnormally high amount of CAG repeats (glutamine repeats) in the huntingtin 
(HTT) gene. The number of CAG repeats a person has directly affects the 
likelihood of symptom development. Normal amounts of glutamine repeats falls 
under 28 and from 28-34 the person will not develop HD but the next generation 
could (NINDS 2016).  
Early signs of HD are often noticed by family members when a person 
becomes uncharacteristically irritable, indifferent or passive, depressed, or has 
bouts of anger. Other early signs of HD can affect various cognitive functions 
that lead to impairments in driving, handwriting, memory, or decision making. 
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Difficulty in face, hand and feet movements as well as balance issues may also 
arise. In some cases chorea develops, which is the involuntary and sometimes 
jerky movements of the hands or feet: this can lead to difficulty in walking and 
increase the likelihood of falls (NINDS 2016). Diagnosis involving a physical 
examination, answers to questions, and a review of family history may be 
performed as well as pre-natal genetic testing to determine risk. Once diagnosed, 
usually around 30-40 years of age, the life expectancy is between 10-30 years. The 
increased dependence on family members often leads to extreme depression, 
leading to the second most common cause of death in HD patients: suicide (Roos 
2010).   
Scientists are studying the role of normal HTT in humans. Thus far the 
exact function is unknown, however; it is believed HTT plays a role in normal 
nerve cell function and development (Cattaneo et al.2005). Glutamine repeats of 
35-39 are at an increased risk of HD development, some will and some won’t, 
however; the next generation is at an increased risk. Any amounts of repeats over 
40 and the patient will unquestionably develop Huntington’s disease (NINDS 
2016). This increased number of repeats causes medium spiny neurons to become 
vulnerable to apoptosis in the striatum. Nerve cell dysfunction and death affects 
the basal ganglia of the brain, progressing HD (Reiner et al.1988). The basal 
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ganglia are comprised of several different parts and HD targets particular 
regions:  the neurons of the striatum, specifically those in the caudate nuclei and 
the pallidum as well as the area of the brain that controls thought, perception, 
and memory- the cortex. The cell death in these regions cause many symptoms 
that can vary based on the disease progression (Roos 2010). Hippocampal 
dysfunction has also been implicated in HD. Clinical studies involving pre-HD 
(not yet presenting motor symptoms) and HD patients indicated cognitive 
impairment through learning and memory tests (Begeti et al 2016).  Here, they 
subjected patients to a virtual Morris Water Maze (MWM). In rodent models, this 
learning and memory test examines the animal’s ability to find a hidden platform 
in water as well as its ability to remember where it is based on visual cues on the 
wall in order to find it faster the next time. In the virtual MWM, patients used a 
computer program and a joystick to “swim” through a pool to find the 
submerged platform. This study found that HD, but not pre-HD, patients had 
impaired learning and memory compared to the control (Begeti et al 2016).  This 
data provides evidence towards hippocampal dysfunction in Huntington’s 
disease.    
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Parkinson’s disease 
Parkinson’s disease (PD) was first described by James Parkinson in 1817. 
PD deteriorates the dopamine neurons in the substantia nigra of brain: dopamine 
sends a chemical message to the part of the brain that controls movement and 
coordination. As it progresses, patients lose their ability to control normal 
movement. This can be described by the acronym TRAP; referring to the tremors 
at rest, rigidity, akinesia (or bradykinesia) and postural instability that are tell-
tale signs of PD (Parkinson 1817; Jankovic 2008). Other complications include 
difficulty in speech, swallowing, memory loss, and depression (Simon and Zieve 
2012). Neuron loss is pronounced in the Lewy bodies (LB) but the 
neurodegeneration also occurs throughout the central nervous system (CNS) 
(Thomas and Beal 2007). Lewy bodies are abnormal aggregates of proteins that 
develop inside the cells of the substantia nigra. These aggregations causes cell 
death which could, in turn, release the LB into the neuropil. The presence of LB 
in the substantia nigra is a tale tells sign that the individual has Parkinson’s 
disease. So much so, that the absence of LB automatically dismisses PD as a 
possible diagnosis (Gibb and Lees 1988). The exact cause of Parkinson’s disease is 
ultimately unknown; however, it is believed that combinations of genetic and 
environmental factors are to blame. The majority of PD cases (>90%) are sporadic 
17 
 
 
 
while familial is rarer (<10%).  In those familial cases, studies have found several 
genes that are believed to have a role in PD pathogenesis: Park1 (α-synuclein), 
Park7 (DJ-1), Park6 (pink1), Park8 (LRRK2) (Thomas and Beal 2007). Α-synuclein 
in particular makes up nearly 1% of all proteins expressed in the cytosol of brain 
tissue. Specifically, expression is seen in the neocortex, hippocampus, substantia 
nigra, thalamus, and cerebellum (Kruger et al. 1998; Zarranz et al. 2003). It was 
found that one of the major components of Lewy bodies is α-synuclein fibrils, 
which further explains α-synuclein’s role in PD pathogenesis (Spillantini et 
al.1997). The exact function of α-synuclein is unknown; however, point 
mutations of the SNCA gene of A53T or A30P amino acid change resulted in 
early onset PD (before 40 years old) with autosomal dominant inheritance 
(Kruger et al. 1998; Zarranz et al. 2003). Immunohistochemistry has revealed that 
SNCA is strongly expressed in Lewy bodies and especially in the “halo” of LB’s 
(Spillantini et al.1997; Spillantini et al.1998; Baba et al.1998). 
Onset of PD typically occurs in adults between the ages of 55-75 with less 
than 10% occurring in people under 40. Other risk factors include gender and 
race: men are diagnosed more often than women and African-Americans and 
Asian-Americans are at a reduced risk compared to Caucasians (Simon and 
Zieve 2012). Treatments to cope with the symptoms and attempt to delay 
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Parkinson’s disease include dopaminergic drugs and therapy as well as lifestyle 
changes such as high protein/fiber diets and physical therapy (Jankovic 2008; 
Simon and Zieve 2012).  It is said that a person will not die from PD, but with it; 
this meaning the disease itself doesn’t cause death but the complications that 
arise from PD symptoms may reduce longevity. Struggles in motor control may 
cause falls and swallowing difficulties could lead to food being aspirated into the 
lungs and cause pneumonia (Marttila and Rinne 1991; Simon and Zieve 2012).  
Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS or also known as Lou Gehrig Disease) 
is a progressive neurodegenerative disease that affects the neural cells of the 
brain, brainstem, and spinal cord. When these cells die it also causes the motor 
neurons to die, which leads to muscle atrophy and loss of motor control and 
movement. ALS patients may become paralyzed as the disease progresses as 
well as lose the ability to swallow, breathe, or perform other basic functions 
(Johnston et al.2001). Although ALS is known to affect muscular tissue, it has 
also been found to affect cognitive functions like personality change, irritability, 
obsessions, poor insight, and frontal executive deficits. These deficits are 
characteristic of frontotemporal dementia with symptoms that influence verbal 
fluency, attention, and working memory (Phukan et al.2007). Some of the 
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cognitive deficits that resemble Alzheimer’s is that there was decrease work 
fluency, loss of attention, and memory impairments. In one clinical study, a 
patient with ALS was previously diagnosed with AD before any muscular 
symptoms developed. There was neuronal loss in the parahippocampal gyrus of 
11/14 cases reviewed. This study revealed that there are specific hippocampal 
lesions in ALS that involve the connections between the tranentorhinal cortex 
and the outer layer of the dentate gyrus: both within the hippocampus. 
Hippocampal lesions in ALS were distinctive from the lesions and connections 
found in AD. (Takeda et al.2008). 
 Most cases (90%-95%) of ALS cannot be traced to a gene mutation that 
was passed from a family member: sporadic ALS (SALS). Sporadic ALS is 
believed to be caused by the environmental effects on the genome over the 
lifespan of a person ("Amyotrophic Lateral Sclerosis" 2015). Mutations in the 
Copper-Zinc superoxide dismutase (SOD1) gene are associated with around 20% 
of autosomal dominant familial ALS (FALS) and 2% of (SALS). Other genes that 
have been shown to be associated with various forms of FALS are alsin (ALS2), 
senataxin (ALS4), C9ORF72, and vesicle associated membrane protein B- VAPb 
(ALS8); which is a member of the vesicle associated membrane protein VAMP-
associated protein family (Wijesekera and Leigh 2009; Blitterswijk 2012).  
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Like many neurodegenerative diseases, ALS is associated with the 
aggregation of misfolded proteins. Some of these cytoplasmic inclusions or 
aggregates are found in degenerating motor neurons as well as the surrounding 
oligodendrocytes. These aggregates can be found in the spinal cord as well as 
other regions, including the frontal and temporal cortices, hippocampus, and 
cerebellum (Al-Chalabi et al 2012). Proteins seen to aggregate in these regions in 
many ALS cases are VAPb, SOD1, and TDP-43 (Nishimura et al 2006, Rosen et al 
1993, Arai et al 2006, Neumann et al 2006). 
ALS8 is an autosomal dominant form of FALS that was first identified in 
Brazilian families; however, it has also been found in Europe and Asia 
(Nishimura et al.2004b; Funke et al.2010; Millecamps et al.2010). The VAPB gene 
conveys directions for making a protein that is found throughout the cells in the 
body.  The normal function of the VAPb protein, however, is poorly understood. 
What is known is that VAPb is associated with the membrane that surrounds the 
endoplasmic reticulum (ER). It is believed that VAPb plays an important role in 
unfolded protein response. This is so a buildup of misfolded or unfolded 
proteins does not occur and the ER and function effectively (Hartz 2001). VAPb 
mutations have been shown to be associated with motor neuron death as well as 
speed of disease progression (Tsuda et al.2008). The mutation in VAPb that has 
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been shown to be associated with ALS8 is a substitution of a proline by a serine 
at position 56 (P56S). VAP-33-A is the P58S Drosophila homolog of P56S VAPb 
and has been found to prevent normal proteolytic processing that is required for 
the release of an N-terminal fragment thought to provide trophic support at the 
neuromuscular junction (Tsuda et al 2008). Deletion of endogenous VAPb causes 
late onset motor deficits in mice as well escape response defects in zebrafish 
(Kabashi et al 2013). Overexpression of P58S in flies or P56S in mice and 
mammalian cell lines have also been found to sequester wild-type VAPB in a 
dominant negative effect that produces a phenotype similar to VAPB deletion 
(Tsuda et al 2008). There also may be a toxic gain of function, which is supported 
by the discovery of TDP43-positive aggregates in the spinal motor neurons of 
aged P56S transgenic mice but not in mice overexpressing wild-type VAPB 
(Tudor et al 2010). Exogenous and P56S VAPb are also expressed in hippocampal 
neuron cells along with in HEK293 cell cultures (Nishimura et al.2004a).  
Sporadic ALS occur 1 in 400 people by the age to 70 with onset being 
between the ages 55-65. Both SALS and FALS occur in men more often than 
women; however, prevalence seems to be reaching equilibrium. Treatments for 
ALS are limited to managing the symptoms instead of the disease. Drugs as well 
as psychological support, comfort, and physical therapies are often used to 
combat the symptoms as the disease progresses. ALS is a fast acting disease and 
22 
 
 
 
prognosis is short; typically, patients survive 2-5 years after diagnosis 
(Wijesekera and Leigh 2009). 
These neurodegenerative disorders, and others, are vastly devastating for 
those afflicted and their family that cares for them. The debilitating effect on the 
brain and function which occurs in patients combined with the high prevalence 
within the population raises concern, and prompts researchers towards finding 
treatments and cures. Epigenetic treatment is one of many ways scientists are 
exploring to aid in the rescue of these symptoms.  
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CHAPTER II: INTRODUCTION 
Epigenetics of Neurodegenerative Disorders 
 Several neurodegenerative disorders have been found to have epigenetic 
components. These elements could provide the necessary information to 
uncovering treatments and therapies by targeting specific epigenetic hallmarks 
of a given disease.  
Alzheimer’s disease 
The HAT Tip60 has been associated with Alzheimer’s disease due to its 
interaction with the processed C-terminal APP intracellular domain (AICD). This 
domain has been shown to form a transcriptionally active protein complex with 
Tip60 to aid in the epigenetic regulation of transcription via histone acetylation 
(Cao and Sudhof 2001; Cao and Sudhof 2004). The authors concluded from this 
that a co-expression of APP along with a deficiency of Tip60 lead to increased 
neuronal cell death; whereas, the expression of APP with wild type Tip60 
reduced cell death. Based on these findings, it is thought that Tip60 could play a 
neuroprotective role due to its function in histone acetylation (Cao and Sudhof 
2001; Cao and Sudhof 2004; Müller et al.2008).  Expanding on this, a previous 
study tested whether selectively depleted Tip60 or overexpression of Tip60 in the 
mushroom body of Drosophila would affect memory and learning (Xu et.  al 
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2014).  The flies that had depleted Tip60 activity displayed both mushroom body 
defects, such as thinner and truncated axonal lobes, as well as memory and 
learning impairments: demonstrated by performance in a courtship assay.  When 
APP flies (AD model) were crossed with flies that overexpressed Tip60, there 
were no morphological defects and it was found that both the mushroom body 
and the memory and learning deformities were rescued. These memory and 
learning defects resemble that of APP induced Alzheimer’s disease. This study 
uncovered an important role Tip60 has in the cognitive function of 
neurodegenerative disorders and thus possible therapeutic techniques that could 
be implicated via neuroprotective Tip60 (Xu et.  al 2014).   
The effects and epigenetic interactions of Tip60 on this particular 
neurodegenerative disorder were profound; therefore it is of interest to 
investigate the effects on other neurodegenerative disorders, which leads to the 
following question: 
Will overexpression of the histone acyltransferase (HAT) Tip60 
in the mushroom body of Drosophila ameliorate any deformities 
or behavioral abnormalities found in models of Huntington’s 
disease, Parkinson’s disease, and/or amyotrophic lateral 
sclerosis (ALS)? 
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Huntington’s disease 
Huntington’s disease is characterized by the abnormal polyglutamine 
repeat in the huntingtin (Htt) gene. Studies have shown that this mutant gene 
directly interacts with HAT’s such as CBP and causes transcriptional issues by 
binding to HAT domains and reducing H3 and H4 acetylation levels (Gray 2010; 
Steffan et al., 2001). These studies have also shown that Htt recruits HDAC’s, 
effectively compressing the chromatin structure further (Gray 2010). 
Dysregulation of histone acetylation was first observed with a CREB-binding 
protein (CBP), which has histone acetyltransferase (HAT) activity, and it was 
found intracellularly in in vitro preparations of animal model brains as well as 
postmortem tissues from HD patients. This suggests that the decrease of soluble 
CBP may affect the transcriptional regulation of neuronal genes involved in cell 
survival (Valor and Guiretti 2014). Inhibiting HDAC’s (HDACi) with various 
chemicals have shown to rescue the decreased histone acetylation levels. This 
rescue leads to improvements in the neurodegenerative symptoms in various 
Drosophila and mouse models of Huntington’s disease (Steffan et al.2001). One 
particular HDACi, pimelic diphenylamide, has also shown favorable effects on 
the disease phenotype and transcriptional anomalies in HD mouse models 
(Thomas et al.2008). In these studies, there was either a decreased amount of 
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HAT’s or an increased amount of HDAC’s that helped slow or prevent the 
progression of the disease. This indicates that an underlying cause of 
Huntingdon’s disease is a down regulation of HAT’s; therefore the 
overexpression of a HAT, like Tip60, in a Drosophila model of Huntington’s 
disease may induce rescue by correcting these imbalances (Valor and Guiretti 
2014; Gray 2010; Steffan et al.2001; Thomas et al.2008). 
Parkinson’s Disease 
Abnormalities in histone acetylation have also been found in the 
pathogenesis of Parkinson’s disease (PD). A presynaptic protein which is 
associated with familial PD and is localized in the nucleus and presynaptic nerve 
terminals, α-Synuclein, was found to bind to histone H3 in the chromatin 
structure (Kontopoulos et al.2006).  Accumulation of α-Synuclein on the histones 
causes “histone masking”, which shields the histones from becoming acetylated 
(Feng et al.2015).  When this occurs, it inhibits various HAT’s and triggers the 
apoptosis of neuronal cells- resulting in Parkinson’s disease progression. 
Treatment with sodium butyrate has shown to rescue the toxicity of α-Synuclein 
(Kontopoulos et al.2006) as well as improved the locomotor deficits and early 
mortality in a rotenone-induced Drosophila model of PD (Laurent et al.2013). 
Sodium butyrate is a small fatty acid derivative that can inhibit both class I and 
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class II HDAC’s. This inhibition causes acetylation of the histones to increase and 
therefore reduce the toxicity of α-Synuclein (Laurent et al.2013). The use of an 
HDACi to rescue PD symptoms has been successful in previous studies; 
therefore, increasing the acetylation levels in α-Synuclein PD models via 
overexpression of the HAT Tip60 may also induce rescue.  
Amyotrophic Lateral Sclerosis 
Previous studies have found that inhibiting histone deacetyltransferases 
have also aided in the prevention of ALS pathogenesis. In one of these studies, 
mice were treated with lithium and valproate and there was a delayed onset of 
the disease, as well as reduced neurological insufficiencies and prolonged 
survival. In SOD1 mice, treatment with trichostatin A or valproate also showed 
to hinder disease progression along with increasing survival (Coppedè 2013). 
SOD1 mutations have also been shown to reduce levels of CBP (a HAT) in motor 
neurons along with the ALS symptoms; therefore a treatment of sodium 
valproate (an HDACi like compound) was used to try and ameliorate the 
acetylation levels. This treatment wasn’t able to prolong survival; however, it 
was able to suppress motor neuron death and reestablish histone acetylation 
levels (Rouaux et al.2007). ALS patients were also involved in a phase II clinical 
study involving sodium phenylbutyrate (Cudkowicz et al. 2009) or valproic acid 
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treatments, both HDACi’s (Piepers et al. 2009). Treatment with sodium 
phenylbutyrate proved to increase the histone acetylation levels and was safe 
and bearable for the patients use (Cudkowicz et al. 2009). Treatment with the 
valproic acid, however, did not provide the same results. Use of valproic acid in 
the ALS patients did not produce and significant benefits in delaying the 
symptoms (Piepers et al. 2009). Many of the studies mentioned point toward an 
abnormally low amount of histone acetylation due to increased HDAC activity as 
the cause of disease progression. This suggests that overexpressing a HAT, such 
as Tip60, to counterbalance the HDAC’s could also aide in the rescue of ALS 
symptoms.   
Fly Models (Stocks) 
Appropriate fly models (stocks) for each of the diseases are crucial to 
successfully replicating each disease phenotype in order to view and rescue 
mushroom body deformities. The mutated ALS associated protein VAPb has a 
Drosophila homologue VAP-33-A. In an ALS model that expresses the VAP gene 
it has been found that the mushroom bodies in both the late larvae and adult fly 
brains lack the alpha (α) lobes.  Additionally, using a flight assay, they observed 
that the fly’s flight ability was hindered (Tsuda et.  al 2008). This model should 
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affectively help determine if behavioral abnormalities are rescued due to Tip60 
overexpression.    
Nno literature was found pertaining to explicit mushroom body 
abnormalities in Huntingdon’s or Parkinson’s Drosophila models.  Therefore, 
models of these diseases will be used and behavioral phenotypes will be assessed 
to determine if Tip60 ameliorates those as well.  For the Huntingdon’s model, 
flies that exhibit polyglutamine extensions of 128 and 93 were found to have 
abnormalities when subjected to a larval crawling assay.  These larvae displayed 
less turns and covered a shorter distance than the wild type larva.  (Steinert et.  al 
2012).  In A30P and A53T α-synuclein Parkinson’s model flies, a negative 
geotaxis assay was performed and the climbing abilities of the transgenic adult 
flies were substantially reduced (Jahromi et.  al 2015).  This provides evidence 
that all models have displayed some form of behavioral deficiency and therefore 
are viable models for Tip60 rescue. 
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CHAPTER III: MATERIALS AND METHODS 
Drosophila Stocks 
All fly models used were obtained from Drosophila Stock Center 
(Bloomington, IN, USA). The specific models used are described in Table 1. Flies 
were maintained at 25°C on standard cornmeal/agar/molasses medium which 
was supplemented with yeast on a 12‐h light/dark cycle. 
Generated stocks   
Generation of the double transgenic 201y; Tip60 model line listed in Table 
1 follow the same steps as the UAS‐Tip60;APP fly lines that are described in 
(Pirooznia et al. 2012). Balancers were used in the generation of the various 
stocks. These phenotypes are systematically paired with the genotypes so 
selection of desired genotypes (that cannot be visually seen) can occur.  
 In generating the 201y; Tip60 line (Figure 1), flies with the balancer on the 
3rd chromosome (TM3/TM6) were crossed with flies containing homozygous 
201y (2nd chromosome). Flies with the balancer on the 2nd chromosome (Cyo/Sco) 
were crossed with flies containing homozygous Tip60 (3rd chromosome). These 
crosses resulted in the F1 generation being heterozygous for the balancer as well 
as 201y or Tip60. Verification of this genotype can be viewed in the orange eyes 
and the balancer phenotype outlined in Table . These flies were then self-crossed 
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with their balancer counterpart (i.e TM3 with TM6 and Cyo with Sco) as to have 
progeny homozygous for 201y or Tip60 genotype and both balancers Cyo or 
TM3 being selected. This can be viewed by the red eye color and either curly 
wings (Cyo) or stubbly hair on the back (TM3). Another self-cross was performed 
and the subsequent offspring that displayed both balancer phenotypes (Cyo and 
TM3) as well as red eyes were selected. These phenotypes are indicative of the fly 
being heterozygous for 201y and Tip60. A final self-cross was executed and flies 
of normal phenotype and red eyes were selected. A normal phenotype with red 
eyes indicated that the balancers are no longer present and the fly is homozygous 
for 201y and Tip60.  
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Table 1: Fly stocks utilized in experiments. 
Name Genotype 
Simplified 
Genotype 
Description Source 
Wild Type W1118 W1118 Control fly Flybase 
Huntington’s 
Disease 
P{w[+mC]=ActGFP}38, 
w[1118]; C(1)DX, 
P{w[+mC]=hs-hid}18A, 
y[1] w[1] f[1]; 
P{w[+mC]=UAS-
HTT.128Q.FL}f27b 
UAS-Htt 
(128Q) 
Htt mutation of 
128 
polyglutamine 
(Q) repeats 
under UAS 
control 
Flybase 
Parkinson’s 
Disease 
w[*]; P{w[+mC]=UAS-
Hsap\SNCA.A30P}40.1. 
UAS- 
Hsap/SNCA 
expresses 
human mutant 
A30P form of 
alpha-synuclein 
under UAS 
control 
Flybase 
Amyotrophic 
Lateral 
Sclerosis 
y[1] w[*]; 
P{w[+mC]=UAS-Vap-33-
1.P}3. 
UAS-Vap-
33-1 
overexpresses 
Vap-33-1 under 
UAS control 
Flybase 
Gal4 driver- 
201Y 
201Y 201Y 
expresses in the 
mushroom 
body 
Flybase 
Balancer- 
Cyo/Sco 
Cyo/Sco Cyo/Sco 
2nd 
chromosome: 
curly wings 
(Cyo) and less 
bristles (Sco) 
Flybase 
Balancer-
TM3/TM6 
TM3/TM6 TM3/TM6 
3rd 
chromosome: 
stubbly hair on 
its back (TM3) 
and 
ultrabithorax 
(TM6) 
Flybase 
GFP 
y[1] w[*]; 
P{w[+mC]=UAS-
GFP::lacZ.nls}15.3 
GFP 
2nd 
chromosome: 
expresses GFP 
Flybase 
Generated 
Line 
201y; Tip60 201y; Tip60 
Homozygous 
for 201y and 
Tip60 
(Figure 1) 
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Figure 1: Schematic of crosses performed to generate homozygous 201y; Tip60 
flies. 
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Behavioral Tests 
Larvae crawling assay 
 A single third instar larva was placed on a petri plate of 1% agar which 
was positioned on a 0.2cm2 grid paper (Figure 2). The larva was allowed to 
acclimate to the plate for 5 minutes before data collection. The number of grid 
lines the head of the larva passed in 30 seconds was recorded. This was 
performed a total of three times for each larvae and averaged. Data from thirty 
larvae was collected (Nichols et. al 2012, Mudher et al 2004). This was repeated 
for each disease model and WT larvae.  
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Figure 2: Larvae crawling assay with an individual larva on the plate (red 
circle). 
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Longevity assay 
 One hundred flies (50 males/ 50 females) of each model and wild type 
were collected on day 1 and placed in separate vials (Figure 3). Separating the 
males from the females ensures reproduction does not have an effect on 
longevity. Each day the vials were checked to view remaining surviving flies. Fly 
vials were maintained and food was replaced as needed. Vial density did not 
exceed 20-30 flies to ensure no overcrowding (Lorbeck et al. 2010). 
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Figure 3: Drosophila vials containing 100 of each disease model and WT for 
longevity analysis. 
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RNA Extraction and Quantitative PCR (qPCR) 
Total RNA was isolated from larvae brains using the RNeasy Plus Mini 
Kit (QIAGEN). cDNA was prepared using the SuperScript II reverse 
transcriptase kit (Invitrogen) according to the manufacturer’s instructions with 1 
μg total RNA and 0.2μg/ml random hexamer primers (Roche Applied Science). 
PCRs were performed in a 20μl reaction volume containing cDNA, 1μPower 
SYBR Green PCR Master Mix (Applied Biosystems), and 10μM both forward and 
reverse primers.  
Forward and reverse primer sets designed to amplify a 97 base pair non-
conserved region of dTIP60 were 5’GACGGCTCACAAACAGGC3’ and 
5’GGTGTTGCGGTGATGTAGG3’, respectively. Forward and reverse primers 
designed to amplify a 105 base pair region within the 5′UTR region of 
endogenous dTIP60 were 5′CAGTTGTGGTTCACAATTACCC3’ 
and 5′GTGCGCAGAAAGTTATACAGC 3′, respectively. RP49 which encodes the 
Drosophila ribosomal protein L32 was used as an internal standard and reference 
gene using forward and reverse primer pairs 5′CTGCTCATGCAGAACCGCGT3’ 
and 5′GGACCGACAGCTGCTTGGCG 3′, respectively.  This one is the 
housekeeping gene.  
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PCR was performed using an ABI 7500 Real‐ Time PCR system (Applied 
Biosystems) following the manufacturer’s instructions. Fold change in mRNA 
expression was determined by the ΔΔCt method (Livak and Schmittgen, 2001).  
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CHAPTER IV: RESULTS 
Verification of Tip60 overexpression via qPCR 
 After generation of homozygous 201y; Tip60 fly lines (as described in 
Chapter III and illustrated in Figure 1), it is important to verify Tip60 is 
overexpressed in comparison to wild type (201y) flies. This can be accomplished 
by performing qPCR on the larva brains. Larvae are used because the behavioral 
assays performed in this study are on larvae, so the amount of Tip60 in the larvae 
brains correlates with the results better than with adult brains. The brains 
specifically are being tested rather than the whole head to avoid other tissues 
being included in the results.  
 Exogenous and endogenous Tip60 primers were used to include both 
types of protein in the results. This demonstrates the natural Tip60 present in the 
brain (endogenous) as well as the Tip60 that has been added (exogenous) to 
create overexpression.  
 Tip60 levels in the 201Y larvae brains as well as the 201Y, Tip60 generated 
line were quantified. Endogenous Tip60 primers were used since it the natural 
Tip60 that occurs in the brain. Exogenous Tip60  primers were also used since it 
included the Tip60 that was added during generation to increase of overall Tip60 
levels within the larvae brain and create overexpression. There was a 1.5 fold 
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change between the two fly lines (Figure 4). This quantified increase of Tip60 in 
the fly confirms the 201Y; Tip60 fly generation was successful and could 
therefore be utilized to induce rescue via Tip60 action.  
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Figure 4: Tip60 is overexpressed in the brains of 201Y; Tip60 larvae. 
qPCR analysis revealed a 1.5 fold change between the 201Y line and the 
generated 201Y; Tip60 line. 
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Larvae crawling ability in Huntington’s model is rescued by Tip60 
 Huntington’s disease has been shown to affect the hippocampus. Since the 
hippocampus is implemented in locomotive function, a larvae crawling assay 
was executed. Analyzing larval movement, over adult movement, and 
implementation of Tip60 rescue will determine if there are epigenetic changes 
that occur early in the disease progression. 
 Htt (128Q) third instar larvae were analyzed for their crawling ability 
before and after overexpression of Tip60 was introduced. First glances at the data 
looked promising and were quantified with ANOVA statistics (Figure 5). 
Initially, 201Y; W1118 larvae were compared against 201Y; Htt (128Q) larvae and 
were found to be significantly different. When comparing 201Y; Htt (128Q) 
larvae to Htt (128Q); Tip60 rescue larvae, a significant difference was also 
observed. The final comparison for this model was between W1118; Tip60 larvae 
and Htt (128Q); Tip60 rescue larvae. The crawling ability of the disease model 
improved to the point where there was no significant difference between that 
and the wild type larvae. These results indicate that rescue had occurred. 
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Figure 5: Tip60 rescues diminished crawling ability of Huntington's disease 
model larvae. Significant difference of * p<0.0001 was seen between W1118 and 
Htt (128Q) as well as Htt (128Q) and Htt (128Q); Tip60. No significant difference 
between W1118; Tip60 and Htt (128Q).  
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Larvae crawling ability in Parkinson’s model is rescued by Tip60 
Parkinson’s disease gene α-synuclein has been found to accumulate in the 
hippocampus, as well as other structures. The accumulation contributes to the 
pathogenesis of PD. Since the hippocampus is implemented in locomotive 
function, a larvae crawling assay was executed do determine if this function is 
hindered. Analyzing larval movement, over adult movement, and 
implementation of Tip60 rescue will determine if there are epigenetic changes 
that occur early in the disease progression. 
W1118 larvae were first compared to 201Y; Hsap/SNCA. Visually, there 
was a noticeable difference in crawling ability. Upon ANOVA analysis, there was 
a p<0.0001 significant difference between the two. This disease model was then 
compared against the rescue model Hsap/SNCA; Tip60. Here, there was a p<0.05 
significant difference which showed an increase of ability. Most notably was the 
comparison between W1118; Tip60 and Hsap/SNCA; Tip60 rescue: this displayed 
no significant difference (Figure 6). These results indicated that the crawling 
ability of the PD larvae was hindered in some way, and introduction of Tip60 
rescued this hindrance. 
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Figure 6: Tip60 rescues diminished crawling ability of Parkinson’s disease 
model larvae. Significant difference of ** p<0.0001 was seen between W1118 and 
Hsap/SNCA and a significant difference of *p<0.05 was seen between 
Hsap/SNCA and Hsap/SNCA; Tip60. No significant difference between W1118; 
Tip60 and Hsap/SNCA; Tip60 was observed.  
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Larvae crawling ability in ALS model is partially rescued by Tip60 
Hippocampal lesions specific to ALS have been found in several cases 
(Takeda et al.2008). Since the hippocampus is implemented in locomotive 
function, these lesions could affect movement in these models. Therefore, a 
larvae crawling assay was executed do determine if this function is hindered. 
Analyzing larval movement, over adult movement, and implementation of Tip60 
rescue will determine if there are epigenetic changes that occur early in the 
disease progression. 
The wild type (W1118) larvae were compared to the 201Y; Vap-33-1 larvae 
.There was a visible difference in crawling ability between the two as well as a 
p<0.0001 significant difference with ANOVA analysis. This disease model was 
then compared against the rescue model Vap-33-1; Tip60. There was also a 
p<0.05 significant difference which showed an increase of ability. However when 
W1118; Tip60 was compared against Vap-33-1; Tip60 rescue larvae, there was 
still a significant difference of p>0.0001. These results indicate that a partial 
rescue of crawling ability was accomplished (Figure 7).  
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Figure 7: Tip60 partially rescues diminished crawling ability of ALS disease 
model larvae. Significant difference of ** p<0.0001 was seen between W1118 and 
Vap-33-1 larvae and a significant difference of *p<0.05 was seen between Vap-33-
1 and Vap-33-1; Tip60 larvae. A significant difference between W1118; Tip60 and 
Vap-33-1; Tip60 was still observed. 
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Longevity is unaltered in Huntington’s disease model 
Huntington’s disease is often accompanied by an array of complications. 
These can lead to a shortened lifespan of the patient afflicted. For this reason, it is 
important to determine if the HD fly models used display a shorter lifespan 
when compared to wild type files and determine if Tip60 prolongs the lifespan. 
Males and females were collected on day 1 and kept in separate vials. This was to 
ensure mating could not occur and influence the results. Vial density did not 
exceed 20-30 flies to ensure no overcrowding. 
Initial observations of the data suggested the possibility of a partial rescue. 
However, survival log rank analysis revealed that there was no significant 
difference between W1118 and Htt (128Q), Htt (128Q)and Htt (128Q); Tip60 as 
well as no significant difference between W1118; Tip60 and Htt (128Q); Tip60 
(Figure 8). This indicates that lifespan is unaltered in this Huntington’s disease 
model. 
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Figure 8: Longevity is unaltered in Huntington’s disease Model. 
Survival log rank analysis revealed that there was no significant difference 
between the HD model and wild type as well as the HD vs rescue HD, and WT; 
Tip60 vs rescue HD. 
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Longevity is unaltered in Parkinson’s disease model 
 It is said that patients with Parkinson’s disease don’t die from the disease 
itself, but from the complications it causes. This decrease in lifespan may be seen 
in PD fly models as well; therefore it is of interest to examine longevity of the 
models and determine if Tip60 prolongs the lifespan. Males and females were 
collected on day 1 and kept in separate vials. This was to ensure mating could 
not occur and influence the results. Vial density did not exceed 20-30 flies to 
ensure no overcrowding.  
Initial visual analysis of the data was confirmed with a survival log rank 
test. There was no significant difference between W1118 and Hsap/SNCA, 
Hsap/SNCA and Hsap/SNCA; Tip60 as well as no significant difference between 
W1118; Tip60 and Hsap/SNCA; Tip60 (Figure 9). This indicates that lifespan is 
unaltered in this Parkinson’s disease model. 
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Figure 9: Longevity is unaltered in Parkinson’s disease model. Survival log 
rank analysis revealed that there was no significant difference between the PD 
model and wild type as well as the PD model vs rescue PD, and WT; Tip60 vs 
rescue PD.  
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Longevity is unaltered in ALS model 
ALS is said to be a fast acting disease and patients typically survive 2-5 
years after being diagnosed (Wijesekera and Leigh 2009). With this in mind, it is 
of interest to examine the longevity of ALS model flies and determine if Tip60 
prolongs the lifespan. Males and females were collected on day 1 and kept in 
separate vials. This was to ensure mating could not occur and influence the 
results. Vial density did not exceed 20-30 flies to ensure no overcrowding. 
Initial observations of the data indicated the possibility of a partial rescue. 
However, survival log rank analysis revealed that there was no significant 
difference between W1118 and Vap-33-1, Vap-33-1and Vap-33-1; Tip60 as well as 
no significant difference between W1118; Tip60 and Vap-33-1; Tip60 (Figure 10). 
This indicates that lifespan is unaltered in this ALS model. 
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Figure 10: Longevity is unaltered in ALS model. Survival log rank analysis 
revealed that there was no significant difference between the ALS model and 
wild type as well as the ALS vs rescue ALS, and WT; Tip60 vs rescue ALS. 
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CHAPTER V: DISCUSSION 
Larvae crawling ability in Huntington’s model is rescued by Tip60 
 A previous study revealed that larvae with polyglutamine extensions of 
128 and 93 had abnormalities when subjected to a larval crawling assay.  These 
larvae displayed less turns and covered a shorter distance than the wild type 
larva (Steinert et.  al 2012). The model used was the same as in this study (Htt 
(128Q)), however, the Gal4 driver ELAV was used instead of 201Y. This means 
the mutant gene was expressed in all neuronal cells instead of just the mushroom 
body. 
A larva crawling assay was executed to analyze larval movement and 
determine if it is affected by the disease as well as if implementation of Tip60 
overexpression will rescue any changes seen. Larvae crawling ability from wild 
type flies, 201y; Htt (128Q) flies, and Htt (128Q) rescue flies were compared using 
ANOVA statistics. The difference between the wild type and 201y; Htt (128Q) 
flies was significant (Figure 5). This indicates that the mutant gene disrupts the 
mushroom body and causes a deficiency in the locomotive abilities of 
Huntington flies. Early defects, displayed by larvae performance and not adult, 
gives evidence towards changes in the mushroom body early in disease 
progression as well.  
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When 201y; Htt (128Q) larvae were compared to Htt (128Q); Tip60 rescue 
larvae, a significant difference was also observed (Figure 5).  This result is 
indicative of Tip60 overexpression in the mushroom body rescuing the 
locomotive defects seen as well as being important for proper locomotive 
function. Further evidence towards this is the final comparison: W1118; Tip60 vs 
Htt (128Q); Tip60 rescue larvae (Figure 5). There was no significant difference 
between these larvae, which indicated that Tip60 overexpression rescued the 
crawling defects and brought their functions back to a level comparable to that of 
the wild type larvae.   
The rescue seen in the HD larvae is profound in that there is a high 
significance level- higher than the other models tested. This suggests that Tip60 
may provide a particularly important role in neuronal rescue similar to what has 
been found in Alzheimer’s disease (Xu et.  al 2014). In a previous study, similar 
epigenomic and transcriptomic signatures were found between HD and AD 
models- neuronal and inflammation signatures- providing evidence for common 
epigenetic mechanisms and the possibility of comparable treatment (Gjoneska et 
al 2015). 
The diminished crawling ability of the larvae when the mutant gene was 
expressed solely in the mushroom body points towards the possibility of 
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hippocampal involvement in locomotion. The rescue of the crawling ability also 
provides evidence for Tip60 providing a neuroprotective role by restoring the 
HAT/HDAC balance and neural gene expression profiles that is disrupted in 
Huntington’s disease.  This restoration of neural circuitry and function helps to 
lay the groundwork for a broad understanding for the neuroprotective role of 
Tip60 HAT action.  
Larvae crawling ability in Parkinson’s model is rescued by Tip60 
Parkinson’s disease protein α-synuclein has been found to accumulate in 
the hippocampus, as well as other structures and contributes to the pathogenesis 
of PD (Kruger et al. 1998; Zarranz et al. 2003). Since the mushroom body is 
involved in locomotive function, a larvae crawling assay was executed to analyze 
if this function is hindered and determine if Tip60 overexpression will rescue any 
changes seen. Wild type larvae were first compared to 201Y; Hsap/SNCA and 
there was a significant difference between the two (Figure 6). This provides 
evidence towards locomotive deficiency in the PD model occurs and that the 
mushroom body is involved. This disease model was then compared against the 
rescue model (Hsap/SNCA; Tip60) and there was also a significant difference- 
showing an increase of ability (Figure 6). This rise in crawling ability can be 
attributed to the Tip60 overexpression in the mushroom body. In a final 
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comparison, W1118; Tip60 verses Hsap/SNCA; Tip60 rescue displayed no 
significant difference (Figure 6). With no difference between the wild type and 
rescue larvae, there is evidence that epigenetic regulation of Tip60 
overexpression in the mushroom body rescues the crawling defects for PD 
larvae.  
The diminished crawling ability of the larvae when the mutant gene was 
expressed solely in the mushroom body points towards the possibility of 
hippocampal involvement in locomotion. The rescue of the crawling ability also 
provides evidence for Tip60 providing a neuroprotective role by restoring the 
HAT/HDAC balance and neural gene expression profiles that is disrupted in 
Parkinson’s disease.  This restoration of neural circuitry and function helps to lay 
the groundwork for a broad understanding for the neuroprotective role of Tip60 
HAT action.  
Larvae crawling ability in ALS model is partially rescued by Tip60 
Hippocampal lesions specific to ALS have been found in several cases 
(Takeda et al.2008). Since the mushroom body is implemented in locomotive 
function, these lesions found in human patients could possible translate to 
abnormal movement in these models. Therefore, a larvae crawling assay was 
executed do determine if this function is hindered. Analyzing larval movement, 
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over adult movement, and implementation of Tip60 rescue will determine if 
there are epigenetic changes that occur early in the disease progression. 
The wild type (W1118) larvae were compared to the 201Y; Vap-33-1 larvae 
and there was a visible difference in crawling ability between the two as well as a 
significant difference. This disease model was then compared against the rescue 
model Vap-33-1; Tip60. There was also a significant difference which showed an 
increase of ability. However, when W1118; Tip60 was compared against Vap-33-
1; Tip60 rescue larvae, there was still a significant difference. Tip60 was able to 
significantly improve the crawling ability of the disease model; however this 
increase wasn’t enough to be comparable to the wild type larvae. These results 
indicate that a partial rescue of crawling ability was accomplished via Tip60 
overexpression (Figure 7).   
The diminished crawling ability of the larvae when the mutant gene was 
expressed solely in the mushroom body points towards the possibility of 
hippocampal involvement in locomotion. The partial rescue of the crawling 
ability also provides evidence for Tip60 providing a neuroprotective role by 
restoring the HAT/HDAC balance and neural gene expression profiles that is 
disrupted in ALS.  This partial restoration of neural circuitry and function helps 
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to lay the groundwork for a broad understanding for the neuroprotective role of 
Tip60 HAT action.  
Longevity is unaltered in Huntington’s disease model  
Huntington’s disease is often accompanied by an array of complications. 
These can lead to a shortened lifespan of the patient afflicted (Roos 2010). For this 
reason, it is important to determine if the HD fly models used display a shorter 
lifespan when compared to wild type files and determine if Tip60 prolongs the 
lifespan. Males and females were collected on day 1 and kept in separate vials to 
ensure mating could not occur and influence the results. 
Initial observations of the data suggested the possibility of a partial rescue. 
However when a survival log rank analysis was performed, it revealed that there 
was no significant difference between W1118 and Htt (128Q), Htt (128Q)and Htt 
(128Q); Tip60 as well as no significant difference between W1118; Tip60 and Htt 
(128Q); Tip60 (Figure 8). This indicates that lifespan is unaltered in this 
Huntington’s disease model. 
The mutant huntingtin gene (Htt (128Q)) was only expressed in the 
mushroom body of the Drosophila via 201Y Gal4 driver. This could be a factor to 
why longevity was not affected. It is possible the mutant gene in the mushroom 
body is not the cause of the shortened lifespan seen in human HD patients (Roos 
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2010) and complications may instead be caused by a different area of the brain. 
These complications could be due to the death of medium spiny neurons in the 
striatum or nerve cell dysfunction and death which affects the basal ganglia of 
the brain (Reiner et al.1988). 
Longevity is unaltered in Parkinson’s disease model  
It is said that patients with Parkinson’s disease don’t die from the disease 
itself, but from the complications it causes (Marttila and Rinne 1991; Simon and 
Zieve 2012). This decrease in lifespan may be seen in PD fly models as well; 
therefore it was of interest to examine longevity of the models and determine if 
Tip60 prolongs the lifespan. Males and females were collected on day 1 and kept 
in separate vials. This was to ensure mating could not occur and influence the 
results. 
Initial visual analysis of the data was confirmed with a survival log rank 
test. There was no significant difference between W1118 and Hsap/SNCA, 
Hsap/SNCA and Hsap/SNCA; Tip60 as well as no significant difference between 
W1118; Tip60 and Hsap/SNCA; Tip60 (Figure 9). This indicates that lifespan is 
unaltered in this Parkinson’s disease model. 
The main causes of death in human PD patients arise from the side effects: 
falling from tremors, choking on food, food aspirations leading to pneumonia 
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(Marttila and Rinne 1991; Simon and Zieve 2012).  Human mutant A30P form of 
α-synuclein was expressed within the mushroom body of Drosophila only. It is 
likely that changes in the MB from this mutation did not cause any complications 
substantial enough to reduce longevity. These results indicate that the cause of 
death due to complications arise from an area of the brain other than the 
hippocampus. Instead, the reduced longevity could be due to the deterioration of 
dopamine neurons in the substantia nigra of brain. This would cause the loss of 
ability to control normal movement (Parkinson 1817; Jankovic 2008). Other 
complications that lead to patient death include difficulty in speech, swallowing, 
memory loss, and depression (Simon and Zieve 2012). These complications were 
no apparent when mutant gene expression was limited to the mushroom body 
(hippocampus).  
Longevity is unaltered in ALS model 
Mutations in the VAPb protein have been shown to be associated with 
motor neuron death as well as speed of disease progression (Tsuda et al.2008). 
VAPb have been seen to be expressed in hippocampal neuron cells along with in 
HEK293 cell cultures (Nishimura et al.2004a). ALS is a fast acting disease and 
patients typically survive 2-5 years after being diagnosed (Wijesekera and Leigh 
2009). Vap-33-1 was expressed in the mushroom body of Drosophila to view if 
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longevity is affected and if so, to test if overexpression of Tip60 would rescue it. 
Males and females were collected on day 1 and kept in separate vials. This was to 
ensure mating could not occur and influence the results. 
Initial observations of the data indicated the possibility of a partial rescue. 
However, survival log rank analysis revealed that there was no significant 
difference between W1118 and Vap-33-1, Vap-33-1and Vap-33-1; Tip60 as well as 
no significant difference between W1118; Tip60 and Vap-33-1; Tip60 (Figure 10). 
This indicates that lifespan is unaltered in this ALS model. 
 Although distinctive hippocampal lesions were found in ALS patients 
(Takeda et al.2008), Vap-33-1 expression in the mushroom body of Drosophila 
did not affect the lifespan significantly: although visually there seemed to be a 
difference. These results suggest that the mutation in Vap-33-1 does not interact 
with the mushroom body in a manner that affects the lifespan of the fly. The 
reduced lifespan may then be attributed to the degradation of neural cells in the 
brain, brainstem, and spinal cord- leading to loss of motor control and movement 
as well as becoming paralyzed and losing the ability to swallow, breathe, or 
perform other basic functions (Johnston et al.2001).  
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CHAPTER VI: FUTURE DIRECTIONS 
Tip60 Levels in Diseased Brain 
Tip60 is misregulated in the brains of Alzheimer’s disease models (Xu et al 
2014), so it may be of interest to quantify the amount of Tip60 in each disease 
model tested here (Johnson et al 2013).  This could be accomplished by crossing 
the disease model with ELAV instead of 201Y. ELAV is a Gal4 driver that will 
express the desired disease gene in all neuronal cells instead of specifically in the 
mushroom body. Since these flies would express the disease gene in all neuronal 
cells, RNA extraction and qPCR could be performed to quantify the levels of 
Tip60 present using the Tip60 specific primers utilized in this study.  If Tip60 
levels are indeed reduced, then this data would further support the hypothesis 
that Tip60 mis-regulation contributes to neurodegenerative disease pathology 
through a HAT/ HDAC imbalance.  
Larvae Learning and Memory Assay 
A large part of neurodegenerative disorders is the loss of memory and 
learning. Previous studies have focused on the learning and memory capabilities 
of Alzheimer model flies. Xu et al (2014) performed a courtship assay on adult 
AD flies to determine cognitive function in relation to Tip60 expression. They 
selectively depleted Tip60 or overexpressed Tip60 in the mushroom body of 
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Drosophila. The flies that had depleted Tip60 activity displayed both mushroom 
body defects, such as thinner and truncated axonal lobes, as well as memory and 
learning impairments.  When AD model flies were crossed with flies that 
overexpressed Tip60, there were no morphological defects and it was found that 
both the mushroom body and the memory and learning deformities were 
rescued. These memory and learning defects resemble that of APP induced 
Alzheimer’s disease (Xu et al 2014).  This study demonstrated the importance of 
Tip60 in cognitive function. 
Due to this finding, it would be useful to determine if the cognitive 
abilities of Huntington’s, Parkinson’s, or ALS model flies are hindered, and 
thereafter rescued, in larvae. Performing a memory assay on larvae disease 
models would help indicate early impairment in the disease, since cognitive 
decline is one of the first symptoms in these neurodegenerative disorders.  
Honjo (2005) found that Canton S wild type larvae have associative 
learning and memory capabilities with sucrose and select odorants (linalool). The 
experiments performed tested the larvae preference for given reinforcer solution, 
like sucrose, and odorants to determine that preference to migrate to the sucrose 
was greater when combined with an associated odorant when compared to 
either compound alone (Honjo 2005). W1118 wild type flies and 201Y flies (just as 
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in this current study) were also examined and similar results were seen- the Gal4 
driver 201Y did not have an effect on learning and memory (P Panikker, 
unpublished data). Since each model would need to be crossed with this driver, 
it needed to be confirmed that 201Y had no effect on disease model behavior. 
The ability for the larvae to correctly sense the odor given (linalool) is vital 
to the success of the learning and memory assay. Olfactory response has been 
indicated as being involved in hippocampal function (Yokato et al 1967). 
Therefore, it is important to rule out olfactory dysfunction as the cause of 
potential poor performance in the learning and memory test. An assay 
specifically for olfactory response would be performed. This would involve 
placing larvae on a plate with the odorant on one side and water on the other. If 
olfactory response is unaffected, then more larvae will travel to the side with the 
odorant.  
Other than olfactory, the gustatory response of the larvae would also be 
vital to correct learning and memory assay performance. The ability for the 
larvae to correctly sense and interpret sucrose as their food source is critical for 
the association of sucrose to the odorant in the assay. It is important to rule out 
gustatory impairment as the cause of poor performance in the learning and 
memory assay. This would ensure the results of the assay are purely based on 
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the larvae ability to learn and remember, and not poor gustatory response.  This 
could be accomplished by placing larvae on a plate that contains sucrose on one 
half and water on the other. If gustatory response is unaffected, then more larvae 
will travel to the side with sucrose- indicating they are capable of interpreting 
that as their food source.  
If the olfactory or the gustatory response is affected by the disease, then 
the larvae memory test cannot be accurately performed. However, these 
responses could be retested after the introduction of increased Tip60 levels. This 
could possibly demonstrate Tip60 rescue of these defects if present.  
If the olfactory and gustatory responses are unaltered by the disease, then 
the larvae could perform the learning and memory test outlined by Honjo (2005). 
Learning would be determined by the larvae’s performance immediately after 
training. If a decline in the amount on the odorant side is seen, compared to 201Y 
larvae, then it could be determined that the disease does affect the learning 
ability in the early stages. Rescue of learning defects could be determined if the 
Tip60 disease models have no significant difference when compared to the 201Y; 
Tip60 larvae alone. Memory would include subjecting several sets of larvae to 
training, then transferring them to a plain plate for predetermined intervals of 
time. After this time, the larvae would be tested again and observed for odor/ 
68 
 
 
 
side preference. The time gap between training and testing would be a 
respectable indicator of training memory. It would be expected that the disease 
larvae would have a faster decline in memory compared to wild type. 
Introduction of Tip60 to the disease models would assess if rescue can occur and 
therefore memory can improve.  
Mushroom Body Imaging 
The mushroom body of AD model Drosophila has shown to have 
morphological deformities as well. This can be seen by fluorescent imaging of the 
mushroom body that indicates there are thinner and truncated lobes (Xu et al 
2014). To view if the Huntington’s, Parkinson’s, and/or ALS models also display 
MB deformities, a model that contained GFP as well as the disease gene would 
have to be generated. This generation would follow the same methods that were 
used in this study to create the 201y; Tip60 lines (Figure 1). However, these 
would be homozygous for GFP protein on the 2nd chromosome as well as 
homozygous for the disease gene on the 3rd chromosome- both of which would 
be under UAS control. These flies could then be crossed with the 201Y Gal4 
driver as to illuminate the mushroom body with GFP and be imaged.  
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Tip60 Effects on Protein Aggregation 
 Another direction that could be explored is the effects Tip60 has on 
protein aggregation. The diseases focused on in this study are all associated with 
protein aggregation- Alzheimer’s disease with Aβ, Huntington’s disease with 
polyglutamine expansion of the Htt protein, α-synuclein in Parkinson’s disease, 
and TDP-43 in ALS. Since Tip60 can acetylate non-histone proteins as well, it 
would be of interest to see if it would affect the protein aggregation seen in these 
diseases. This could be accomplished by isolating the protein from the fly and 
simply centrifuging the tube: causing aggregated proteins to remain in the pellet 
while the soluble (healthy) protein remain in the supernatant. This could then be 
replicated in flies that contain the overexpressed Tip60. If there is less aggregated 
protein in the Tip60 sample, it would provide evidence for Tip60 possibly 
rescuing the aggregation. If this is the case, it would provide a different angle on 
rescue via Tip60 overexpression.  
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